Faisal Humayun

Faisal Humayun

Expertise: Oil and Gas, Electric Vehicles, Emerging Growth Stories

Education: Bachelor of Science, MBA with Specialization in Finance

About Faisal:
Faisal Humayun is an MBA in Finance and a senior research analyst with 14 years of experience in the field of equity, credit, industry and economic research. While working as a senior analyst, he has been involved in financial modelling, valuation analysis and credit rating.

As a freelancer, Faisal has authored over 1,500 articles for various publications that include Seeking Alpha, GuruFocus, Motley Fool, Trading Ideas and Red Pulse. His primary focus is on fundamental analysis using the top-down as well as bottom-up approach to stock selection.

Faisal is also an active trader with focus on price action trading strategy. A combination of long-term investing and short-term trading has produced decent results in a decade long exposure to equity markets. However, his favorite asset class is precious metals.

Additionally, Faisal has been researching cryptocurrencies in the last few quarters. His focus is not on the blue-chip coins, but on emerging altcoins that can be value creators.

You can learn more about Faisal at his profile on LinkedIn.

Recent Articles

3 Lithium Stocks That Could Make Your Grandchildren Rich

These are the lithium stocks for long-term growth as they represent companies with assets that can be cash flow machines.

3 Cannabis Stocks to Buy Before Regulations Get Super Friendly

These are the cannabis stocks to buy as they represent companies with good fundamentals and prospects of accelerated growth.

3 OTC Stocks to Buy for a Massive Meme Rally

These are the OTC stocks to buy as they represent attractive business ideas with stocks that are trading at undervalued levels.

3 Meme Stocks to Buy on the Dip: June 2024

Investors can't miss out on meme stocks to buy on the dip since these represent fundamentally sound ideas with growth acceleration catalysts

3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains

These are the undervalued pharma stocks and represent companies with a deep research pipeline, that provides sustained growth visibility.